Head‐to‐head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury

• DOI: 10.1111/bph.13822
• Publication Date: 2017-04-18T16:20:35Z
• Authors: Christoph Reichet...; Karoline von Websky; Oleg Tsuprykov; Azadeh Mohagheghi...; Luise Gabriele Falke; Sulistyo Emantoko...; Ahmed Abdallah Hasan; Viktoriia Antonenko; Caterina Curato; Jörg Rippmann; Thomas Klein; Berthold Hocher
• Keywords: Vildagliptin; Linagliptin; Dipeptidyl peptidase

Results regarding protective effects of dipeptidyl peptidase 4 (DPP4) inhibitors in renal ischaemia-reperfusion injury (IRI) are conflicting. Here we have compared structurally unrelated DPP4 a model IRI.IRI was induced uninephrectomized male rats by artery clamping for 30 min. The sham group but not subjected to IRI. or vehicle were given p.o. once daily on three consecutive days prior IRI: linagliptin (1.5 mg·kg-1 ·day-1 ), vildagliptin (8 ) and sitagliptin (30 ). An additional received until study end (before ; after 15 ).Plasma-active glucagon-like peptide type 1 (GLP-1) increased threefold fourfold all inhibitor groups 24 h Plasma cystatin C, marker GFR, peaked 48 Compared with the placebo group, inhibition did reduce plasma C levels. ameliorated histopathologically assessed tubular damage varying degrees drug-specific efficacies. Renal osteopontin expression uniformly reduced inhibitors. IRI-related cytokine decreased inhibition. activity at significantly inhibited only numerically prolonged/dose-adjusted group. Active GLP-1 levels treatment group.In IRI, alter glomerular function, may protect against damage.